Cytodyn Financial Statements From 2010 to 2024

CYDY Stock  USD 0.14  0.00  0.00%   
Cytodyn financial statements provide useful quarterly and yearly information to potential Cytodyn investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Cytodyn financial statements helps investors assess Cytodyn's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Cytodyn's valuation are summarized below:
Cytodyn does not presently have any fundamental signals for analysis.
Check Cytodyn financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cytodyn's main balance sheet or income statement drivers, such as , as well as many indicators such as . Cytodyn financial statements analysis is a perfect complement when working with Cytodyn Valuation or Volatility modules.
  
This module can also supplement various Cytodyn Technical models . Check out the analysis of Cytodyn Correlation against competitors.

Cytodyn OTC Stock Shares Owned By Insiders Analysis

Cytodyn's Shares Owned by Insiders show the percentage of outstanding shares owned by insiders (such as principal officers or members of the board of directors) or private individuals and entities with over 5% of the total shares outstanding. Company executives or private individuals with access to insider information share information about a firm's operations that is not available to the general public.

Insiders Shares

 = 

Executives Shares

+

Employees

More About Shares Owned By Insiders | All Equity Analysis

Current Cytodyn Shares Owned By Insiders

    
  7.91 %  
Most of Cytodyn's fundamental indicators, such as Shares Owned By Insiders, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytodyn is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Although the research on effects of insider trading on prices and volatility is still relatively inconclusive, and investors are advised to pay close attention to the distribution of equities among company's stakeholders to avoid many problems associated with the disclosure of price-sensitive information.
Competition

Based on the latest financial disclosure, 7.914% of Cytodyn are shares owned by insiders. This is 47.87% lower than that of the Biotechnology sector and 44.19% lower than that of the Health Care industry. The shares owned by insiders for all United States stocks is 21.57% higher than that of the company.

Cytodyn Fundamental Drivers Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Cytodyn's current stock value. Our valuation model uses many indicators to compare Cytodyn value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Cytodyn competition to find correlations between indicators driving Cytodyn's intrinsic value. More Info.
Cytodyn is number one stock in return on asset category among its peers. It also is the top company in current valuation category among its peers . Comparative valuation analysis is a catch-all model that can be used if you cannot value Cytodyn by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Cytodyn's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.

About Cytodyn Financial Statements

Cytodyn investors use historical fundamental indicators, such as Cytodyn's revenue or net income, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cytodyn. Please read more on our technical analysis and fundamental analysis pages.
CytoDyn Inc. operates as a clinical-stage biotechnology company. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington. Cytodyn operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 23 people.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cytodyn OTC Stock Analysis

When running Cytodyn's price analysis, check to measure Cytodyn's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cytodyn is operating at the current time. Most of Cytodyn's value examination focuses on studying past and present price action to predict the probability of Cytodyn's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cytodyn's price. Additionally, you may evaluate how the addition of Cytodyn to your portfolios can decrease your overall portfolio volatility.